English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Significance Glioblastoma multiforme (GBM) is the most malignant brain tumor. The recurrence or chemoresistance of GBM is attributed to the presence of cancer stem cells (CSCs). Although many studies indicate that CD133 protein is a biomarker for GBM CSC (GSC) enrichment, CD133 is not specific for GSCs and is also present on cancer cells. In this study, we report that ganglioside D3 (GD3) is not only an alternative marker but also an additional marker to CD133 for the identification and enrichment of GSCs. We further prove that the properties of CSCs in GBM are suppressed when GD3 synthase is inhibited, supporting GD3 as a GBM stem cell marker and a promising therapeutic target for GBM treatment.

Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity